Can Lowering Cholesterol Prevent Or Treat Alzheimer’s?

TL;DR

For listenersOffer from Amazon

Turn your wind-down time into listening time

• Thousands of audiobooks, podcasts and originals
• Listen on your phone, tablet or Echo — also offline
• Cancel anytime

Try Audible free →Free trial for new members

As an affiliate, we earn on qualifying purchases.Hide

Evidence on cholesterol-lowering drugs and Alzheimer’s remains mixed. A Danish observational study found lower dementia risk among people with Type 2 diabetes who used statins, while a Phase 3 trial of obicetrapib reported a change in a blood biomarker in a subgroup carrying the ApoE4 gene. Neither result establishes that these drugs prevent or treat Alzheimer’s.

Two recent lines of research have renewed questions about whether cholesterol-lowering drugs could affect Alzheimer’s: a Danish observational study associated statin use with lower dementia risk in people with Type 2 diabetes, and a Phase 3 trial of the experimental drug obicetrapib found lower levels of an Alzheimer’s-related blood biomarker in a subgroup carrying the ApoE4 risk gene. Neither finding shows that the drugs prevent or treat Alzheimer’s, and a dedicated trial is still needed to test whether biomarker changes correspond to cognitive benefit.

In a study published in Lancet Regional Health Europe, researchers led by Dr. Shoaib Afzal of Copenhagen University Hospital examined electronic health records for more than 130,000 people with Type 2 diabetes. The study found that people who began statins earlier had a 15% lower dementia risk over a decade, while those who started later had a 10% lower risk, compared with the study’s reference groups. The findings are observational: they show an association, not proof that statins caused the difference.

Afzal told Being Patient that the researchers could follow participants for nearly 20 years. But Mayo Clinic neurologist Dr. David Knopman cautioned that people who take statins may differ from non-users in medical knowledge and health behaviors, making the groups difficult to compare. The report also notes that a randomized trial in healthy adults over 70 did not find that statins prevented dementia. Earlier statin trials likewise did not show treatment of cognitive decline.

The separate drug finding involves obicetrapib, a CETP inhibitor developed by NewAmsterdam Pharma. In a subgroup of 1,727 participants carrying ApoE4 in a Phase 3 trial involving people with heart disease or genetically driven high cholesterol, the drug lowered blood levels of pTau-217, a biomarker used in Alzheimer’s assessment. The trial was not described as a test of Alzheimer’s symptoms or prevention. The company has enrolled its first participant in a Phase 2b Alzheimer’s study that will examine whether one year of treatment changes biomarkers in people with disease hallmarks but no symptoms.

From Cholesterol Levels to Brain Biomarkers

The findings matter because they point to two different research questions: whether long-term cholesterol treatment is associated with lower dementia risk, and whether a newer drug can alter a biological marker linked to Alzheimer’s. The Danish results could inform debate about prevention, while the obicetrapib result offers a reason to test the drug in a population selected for Alzheimer’s-related features.

But a shift in pTau-217 is not the same as a change in memory, daily function, or disease progression. Researchers will need clinical evidence before concluding that obicetrapib helps patients. Likewise, observational statin findings do not justify treating Alzheimer’s with statins or changing a person’s medication for that purpose. Statins are used to reduce cardiovascular risk; decisions about their use should be made with a qualified health professional.

Why Statins and Alzheimer’s Differ

Cholesterol in the blood and cholesterol metabolism in the brain are related research topics, but they are not interchangeable. The source report explains that cholesterol from the blood does not enter the brain directly. Statins lower blood cholesterol and reduce cardiovascular risk, but they do not readily reach the brain to alter its cholesterol metabolism.

The ApoE4 gene is associated with increased Alzheimer’s and cardiovascular risk and affects how the body processes cholesterol. That connection has led researchers to investigate whether cholesterol pathways might help explain some disease biology. Still, earlier randomized statin trials did not establish a cognitive benefit, and a recent randomized trial in older adults did not show dementia prevention. The new evidence therefore adds questions rather than overturning those results.

““It’s not realistic that it will ever be done.””

— Dr. David Knopman, Mayo Clinic neurologist, speaking to Being Patient

Biomarker Change Is Not Clinical Benefit

It remains unclear whether the statin association reflects a drug effect or differences between people who start treatment and those who do not. The Danish study’s results cannot settle that question because participants were not randomly assigned to statins for dementia prevention.

For obicetrapib, the reported finding comes from an ApoE4 subgroup in a trial designed around heart disease or genetic high cholesterol. The available report does not establish that the biomarker change improves cognition, delays Alzheimer’s, or prevents symptoms. It also does not provide results from the planned Phase 2b Alzheimer’s study, which is only beginning enrollment. No evidence here supports using cholesterol-lowering medication specifically to prevent or treat Alzheimer’s.

The Alzheimer’s Trial Ahead

NewAmsterdam Pharma’s Phase 2b study will test whether a year of obicetrapib treatment changes Alzheimer’s biomarkers in people who have disease hallmarks but no symptoms. The reported enrollment of the first participant marks the start of that investigation, not a finding about efficacy. Researchers will need to report the trial’s methods and results, including whether any biomarker changes accompany meaningful effects on cognition or daily function.

For statins, the central limitation is the shortage of long-term randomized trials designed to measure dementia outcomes. Knopman and Afzal told Being Patient that such studies may be difficult to fund, in part because statins are off-patent. Until stronger evidence is available, the research supports further study rather than a change in Alzheimer’s prevention or treatment practice.

Key Questions

Do statins prevent Alzheimer’s?

That has not been established. The Danish study found an association between statin use and lower dementia risk among people with Type 2 diabetes, but it was observational. Randomized trials cited in the report have not shown that statins prevent dementia or treat cognitive decline.

What did the obicetrapib study find?

In a subgroup of 1,727 ApoE4 carriers from a Phase 3 trial, obicetrapib lowered blood levels of pTau-217. The reported result concerns a biomarker, not demonstrated improvement in memory or Alzheimer’s symptoms.

Does a lower pTau-217 level mean Alzheimer’s improved?

Not necessarily. The report says the meaning of the change is unknown. A clinical trial must determine whether a biomarker shift is linked to changes in cognition, daily function, or disease progression.

Should someone take a statin to prevent Alzheimer’s?

The findings do not support starting or changing a statin specifically for Alzheimer’s prevention. Statins are prescribed for cardiovascular reasons; people should discuss medication decisions with a qualified health professional.

Source: rss